Reimagining Pharmaceutical Manufacturing: Why the latest E2500-25 Standard Revision Demands Immediate Action
Speed to patient is a primary driver behind the industry’s shift toward modern commissioning and qualification (C&Q) practices while still ensuring product quality and patient...
Read MoreStewardship Over Automation: FDA Redefines AI Accountability in Pharma
In response to a landmark FDA warning, this analysis explores how regulators are shifting from automation to accountable stewardship, redefining governance expectations for AI across...
Read MoreBeyond Batch Testing: What FDA’s Draft Guidance on 21 CFR 211.110 Signals for the Future of Pharmaceutical Manufacturing
How evolving inspection expectations, digital manufacturing, and AI-enabled quality systems are reshaping pharmaceutical control strategies. For many pharmaceutical organizations, the FDA’s draft guidance on Considerations for Complying with 21...
Read MoreResilience in Life Sciences Infrastructure
Uninterrupted operations are essential in today’s pharmaceutical manufacturing environment. Facilities must deliver consistent output without sacrificing quality, even amid complex infrastructure demands, global supply pressures,...
Read MoreEngaging Early: FDA’s Collaborative Pathways for AI in Regulatory Applications (Part 3 of 3)
Nick Armstrong, Senior Director of Digital Enablement at CAI and co-chair of the ISPE Community of Practice on AI, specializes in the intersection of artificial...
Read More